Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Banna

Showing results (891-900 of 991) with videos related to

Pageof 100
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate CancerNicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
International Journal of Molecular Sciences|July 29, 2025
Genotype-Phenotype Correlation of TNF-α (-238, rs361525) and Cystatin C for Early Detection of Sepsis-Associated AKI and Its Severity in Critically Ill NeonatesShimaa Abdelsattar, Hiba S Al-Amodi, Mahmoud Nazih, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Pageof 100

Showing results (891-900 of 991) with videos related to

Sort By:
Pageof 100
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate CancerNicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Clinical Genitourinary Cancer|January 10, 2022
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone StudyDaniele Raggi, Patrizia Giannatempo, Laura Marandino, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
The Oncologist|November 17, 2025
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysisFabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, et al.
Clinical Genitourinary Cancer|November 6, 2023
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9)Alessandra Damassi, Malvina Cremante, Alessio Signori, et al.
The Oncologist|August 3, 2022
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO NetworkPasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, et al.
Clinical Medicine Insights. Oncology|July 22, 2021
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, et al.
International Journal of Molecular Sciences|July 29, 2025
Genotype-Phenotype Correlation of TNF-α (-238, rs361525) and Cystatin C for Early Detection of Sepsis-Associated AKI and Its Severity in Critically Ill NeonatesShimaa Abdelsattar, Hiba S Al-Amodi, Mahmoud Nazih, et al.
European Urology Focus|June 5, 2024
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract CarcinomaCora N Sternberg, Yohann Loriot, Ernest Choy, et al.
Pageof 100